Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model.
about
Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse modelCorrelation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein bindingWhat does it take to synergistically combine sub-potent natural products into drug-level potent combinations?Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpointAnimal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration.In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.Behavior of antibiotics during human necrotizing pancreatitis.Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasisPharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.In vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic miceImpact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.In vivo pharmacodynamics of new lipopeptide MX-2401In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.What do we really know about antibiotic pharmacodynamics?Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin.Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenemPharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.In vivo efficacy of anuran trypsin inhibitory peptides against staphylococcal skin infection and the impact of peptide cyclizationTests for bactericidal effects of antimicrobial agents: technical performance and clinical relevancePopulation pharmacokinetic model for gatifloxacin in pediatric patients.Functional relationship between bacterial cell density and the efficacy of antibiotics.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent ratsIn vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.Chronokinetics of ceftazidime after intramuscular administration to dogs.Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.Antimicrobial blue light inactivation of pathogenic microbes: State of the art.Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Drivers of Iclaprim.
P2860
Q24550534-4BB630F4-AAEC-4628-B168-CF05E723E1CFQ28353204-6B24D4F1-B4BF-40B8-82C1-80422E4F1E48Q28485360-572F5910-C4A2-492B-9D7D-49077E629BA3Q30620954-608EB07D-A30C-46F0-91D4-C6CC85C43224Q30660609-5726B095-CEF9-47D6-B8EB-CDCE0918CF56Q33690950-0F8C1C32-ACF5-4582-988C-3F9BBF567E28Q33753205-B20A5FB3-BF96-4C0F-8AAA-6DDC0A91B4DFQ33980421-5E3E8386-A32D-4938-B7A4-E309C833665DQ33983119-CBEC7E92-9469-4031-A93B-33CFD4090854Q34299028-A7D29C89-5B0B-4329-B0E7-FEDB449CCEBCQ34299064-B4103F4F-689B-4A0A-B5EC-E2695468CC49Q34309486-F6FB9167-B683-4312-9D7C-A4295A7D0CDBQ34320027-E48F2231-60AC-4328-B83E-DCD919531984Q34443407-94F8A62A-8097-459B-A7AC-26A52408D1A6Q35115070-1B51683B-0509-4B44-8010-E0E398A3AE29Q35132306-16876AF1-5527-4A5F-9484-BD47C9E35420Q35168955-EC71FAE1-F454-417E-9D4E-9356EDC27B16Q35169096-EE02D3B9-9497-4E92-BEAD-98DC6BF43ABFQ35474824-C62046BE-4F2C-445A-85BB-6891454ECFE4Q35758967-823921AB-7BF2-42FF-829A-FFE89E1FFD57Q37124158-2B3DBA86-9523-4281-A3A6-F058561D3C8AQ38672016-66FC3955-2684-41B9-9F9E-FCC0206A79AEQ39683724-A038011E-1A9C-44C0-961F-3D014941B349Q39783946-E885FE83-33BF-439D-86DE-422946DD22B5Q40088863-CD9BCA8D-2E66-4B3F-BA9A-76EFD2BFFA7AQ43044202-184B69D3-0973-43F1-AA5A-BB315F53CE8AQ43820901-CF6433B2-8C9B-4E00-B2F6-2CD15BFE16B6Q44284142-8D263E98-0301-4791-A18F-BFFE91E2D920Q47656109-7DF67452-8323-47D7-A8C3-28F4D77C22DEQ48520057-E665F40E-4C58-4937-978F-00DAE1896E9CQ49598797-4C739E16-6F32-4B25-84E8-E89581B527E8
P2860
Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Correlation between in vitro a ...... i in a murine infection model.
@en
type
label
Correlation between in vitro a ...... i in a murine infection model.
@en
prefLabel
Correlation between in vitro a ...... i in a murine infection model.
@en
P2093
P2860
P356
P1476
Correlation between in vitro a ...... i in a murine infection model.
@en
P2093
P2860
P304
P356
10.1128/AAC.35.7.1413
P407
P577
1991-07-01T00:00:00Z